The federal Project Grant award of $396,988 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program. The funding supports research at Western Washington University to optimize non-intoxicating phytocannabinoid-based formulations, specifically cannabidiol (CBD) combined with cannabis-derived terpenes, as a novel treatment approach for Autism Spectrum Disorder (ASD). The 4-year project will empirically assess the therapeutic efficacy of these CBD and terpene compositions on ASD-like phenotypes in a mouse model using electrophysiological, behavioral, and molecular techniques. This comprehensive assessment aims to reveal optimized non-THC cannabis-based treatment approaches for ASD and provide impactful undergraduate research experiences.
Generated 2/25/25, 3:35 AM